


[Home](#) > [Journal](#) > [Medicine & Healthcare](#) > [JDM](#)
[Indexing](#) | [View Papers](#) | [Aims & Scope](#) | [Editorial Board](#) | [Guideline](#) | [Article Processing Charges](#)
[JDM](#) > Vol.2 No.4, November 2012



Visfatin levels are low in subjects with type 2 diabetes compared to age-matched controls

PDF (Size: 163KB) PP. 373-377 DOI: 10.4236/jdm.2012.24058

Author(s)

Subhashini Yaturu, Jared Davis, LaTonya Franklin, Runhua Shi, Prasanna Venkatesh, Sushil K. Jain

ABSTRACT

Background: Visceral adiposity correlates strongly with insulin resistance and components of metabolic syndrome. Visfatin is preferentially produced by human visceral adipose tissue. **Objective:** The objective of this study was to evaluate the relationship between circulating levels of visfatin and other adipocytokines in patients with type 2 diabetes (DM) compared to the age-matched control subjects without DM. **Methods:** Anthropometric parameters, lipid profiles, high-sensitivity CRP (hs-CRP), insulin resistance [HOMA-IR], and levels of visfatin, TNF- α , and resistin were evaluated in 55 subjects with diabetes and 56 age matched control subjects without diabetes. **Results:** The visfatin levels were significantly lower in subjects with diabetes ($p < 0.0001$). Visfatin levels correlated strongly with resistin and CRP. We noted negative correlation of visfatin levels with BMI, triglycerides and glucose. **Conclusion:** These data suggest that visfatin may be a marker of subclinical inflammatory state.

KEYWORDS

Visfatin; Adiponectin; Resistin; Diabetes; Insulin Resistance; TNF- α ; BMI; Metabolic Syndrome; Visceral Adiposity

Cite this paper

Yaturu, S. , Davis, J. , Franklin, L. , Shi, R. , Venkatesh, P. and K. Jain, S. (2012) Visfatin levels are low in subjects with type 2 diabetes compared to age-matched controls. *Journal of Diabetes Mellitus*, 2, 373-377. doi: 10.4236/jdm.2012.24058.

References

- [1] Samal, B., et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. *Molecular and Cellular Biology*, 14, 1431-1437.
- [2] Luk, T., Malam, Z. and Marshall, J.C. (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: A novel mediator of innate immunity. *Journal of Leukocyte Biology*, 83, 804-816. doi:10.1189/jlb.0807581
- [3] Fukuhara, A., et al. (2005) Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. *Science*, 307, 426-430. doi:10.1126/science.1097243
- [4] Li, L., et al. (2006) Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. *Experimental and Clinical Endocrinology & Diabetes*, 114, 544-548. doi:10.1055/s-2006-948309
- [5] Esteghamati, A., et al. (2011) Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. *Diabetes Research and Clinical Practice*, 91, 154-158. doi:10.1016/j.diabres.2010.11.003
- [6] Filippatos, T.D., et al. (2007) Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. *Journal of Endocrinological Investigation*, 30, 323-326.
- [7] Chen, M.P., et al. (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. *The Journal of Clinical Endocrinology & Metabolism*, 91, 295-

[JDM Subscription](#)
[Most popular papers in JDM](#)
[About JDM News](#)
[Frequently Asked Questions](#)
[Recommend to Peers](#)
[Recommend to Library](#)
[Contact Us](#)

Downloads:	56,061
------------	--------

Visits:	113,148
---------	---------

[Sponsors >>](#)

- [8] McGee, K.C., et al. (2011) Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFkappaB and JNK in human abdominal subcutaneous adipocytes. *PLoS One*, 6, e20287. doi:10.1371/journal.pone.0020287
- [9] Kadoglou, N.P., et al. (2010) Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. *Metabolism*, 59, 373-379. doi:10.1016/j.metabol.2009.08.005
- [10] Straburzynska-Lupa, A., et al. (2010) Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis. *Clinical and Experimental Rheumatology*, 28, 19-24.
- [11] Stofkova, A., (2010) Resistin and visfatin: Regulators of insulin sensitivity, inflammation and immunity. *Endocrine Regulations*, 44, 25-36. doi:10.4149/endo_2010_01_25
- [12] Samara, A., et al. (2008) Visfatin, low-grade inflammation and body mass index (BMI). *Clinical Endocrinology (Oxford)*, 69, 568-574. doi:10.1111/j.1365-2265.2008.03205.x
- [13] Esteghamati, A., et al. (2012) The Value of Visfatin in the Prediction of Metabolic Syndrome: A Multi-Factorial Analysis. *Journal of Cardiovascular Translational Research*, 5, 541-546. doi:10.1007/s12265-012-9373-8
- [14] Liu, S.W., (2009) et al. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. *Clinical Endocrinology (Oxford)*, 71, 202-207. doi:10.1111/j.1365-2265.2008.03453.x
- [15] Zhong, M., et al. (2008) Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. *Clinical Endocrinology (Oxford)*, 69, 878-884. doi:10.1111/j.1365-2265.2008.03248.x
- [16] Chang, Y.H., et al. (2011) Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review. *Diabetes Diabetes/Metabolism Research and Reviews*, 27, 515-527. doi:10.1002/dmrr.1201
- [17] Takebayashi, K., et al. (2007) Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. *Metabolism*, 56, 451-458. doi:10.1016/j.metabol.2006.12.001
- [18] Hammarstedt, A., et al. (2006) Visfatin is an adipokine, but it is not regulated by thiazolidinediones. *The Journal of Clinical Endocrinology & Metabolism*, 91, 1181-1184. doi:10.1210/jc.2005-1395
- [19] Oki, K., et al. (2007) Circulating visfatin level is correlated with inflammation, but not with insulin resistance. *Clinical Endocrinology (Oxford)*, 67, 796-800. doi:10.1111/j.1365-2265.2007.02966.x
- [20] Kadoglou, N.P., et al. (2010) Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. *Experimental and Clinical Endocrinology & Diabetes*, 118, 75-80. doi:10.1055/s-0029-1237360
- [21] Peiro, C., et al. (2010) Visfatin/PBEF/Nampt: A new cardiovascular target? *Frontiers in Cardiovascular and Smooth Muscle Pharmacology*, 1, 135. doi:10.3389/fphar.2010.00135